Georgia Lu started her investment career from Cross-Border M&A in CITIC International Asset Management. She founded Magnet Ventures in 2016 and made her first investment in INNFOS, an early-stage robotics company. INNFOS was acquired by CloudMinds in 2018, with Georgia being lead investor and board director prior to acquisition. Subsequent biotech investments by Georgia included Flux Biosciences, HealthTensor, LiliumX, and AtomBioworks from 2018 to 2021.
In 2021, Georgia exited her second investment, Cloudminds, a unicorn robotics company. Following these consecutive exits, she decided to launched Magnet’s first biotech-AI focused fund. Georgia is passionate about working closely with startup founders to realize their vision through focused development, operations and fundraising resource and strategies. A seasoned M&A professional, Georgia has a deep network of corporate and institutional investors to leverage in order to help early stage companies scale.

Shan X. Wang, Ph.D., is the Leland T. Edwards Professor in the Engineering, Professor of Materials Science & Engineering and Electrical Engineering at Stanford University. He also holds courtesy appointments in Radiology. Wang specializes in biosensors, information storage and energy-efficient computing. His research and inventions span across a variety of areas including magnetic biochips, in vitro diagnostics, cancer biomarkers, binding kinetics, epigenetics, and personalized machine learning.
‍
Dr. Wang holds 70 issued and pending patents that have been licensed to more than five companies. He is the scientific founder of MagArray Inc. and several other startups in Silicon Valley. He has published 320 articles, 2 books, and 9 book chapters. Dr. Wang is an inaugural Fred Terman Fellow at Stanford, a Fellow of the Institute of Electrical and Electronics Engineers (IEEE), a Fellow of American Physical Society (APS), and a Fellow of the National Academy of Inventors (NAI). His team won the Grand Challenge Exploration Award from Gates Foundation (2010), the XCHALLENGE Distinguished Award (2014), and the Bold Epic Innovator Award from the XPRIZE Foundation (2017). In 2018 MagArray launched a first of its kind lung cancer early diagnostic assay based on protein cancer biomarkers and support vector machine (SVM), which is now covered by Medicare. Through his leadership positions in the Center for Cancer Nanotechnology Excellence and the Joint University Microelectronics Program (JUMP), Dr. Wang is actively engaged in transformative healthcare and edge-computation research.

Darren Platt has spent his career at the intersection of Genetics and Computer Science, from his early days working on the first percent of the human genome to his current role as Chief Data Officer at Montage Bio. He has held diverse roles, from leading computing at the DOE's Joint Genome Institute to Head of Research at 23andMe when they first launched their product and 15 years designing microorganisms for biomanufacturing at Amyris and Demetrix. At Amyris, Darren oversaw Automation and Computing. At Demetrix, as President, he led the company as it progressed from zero lab space to metric tonne scale production in 4 years. At Exelixis, he developed one of the early computational genomics platforms for model organism-based target identification. He advises the yeast genome database as chair of their SAB, along with a range of companies involved in metabolic engineering, Antibody engineering, data management, small molecule development, and AI-driven fermentation.

Holding a Ph.D. in Computer Science, Darren's research has led to groundbreaking developments in genomic data analysis, DNA design languages,  Neanderthal DNA sequencing, and various patents covering a wide range of computational molecular biology and bioproduction techniques.

Alicia Chung has spent her career in the biotechnology industry spanning drug discovery, clinical development, commercial, corporate/business development and alliance management.  Most recently the SVP of Strategy and Business Development at Bionaut Labs, she led business development, financing and program strategy activities for a first-of-its-kind micro-robotic therapeutics company.  Prior to that, she served as Head of Corporate Development at Amphivena Therapeutics, Inc, a clinical-stage immunotherapy company, and led Strategy and Business Development at Halozyme Therapeutics where she established strategic partnerships with pharma and biotech partners. Alicia began her career at Roche-Genentech, where she completed her post-doctoral training and held positions of increasing responsibility in oncology R&D, commercial and business development, leading asset in-licensing and M&A for the immunotherapy, oncology and hematology franchises. She advises innovation-focused biotechs, leveraging her industry track record and network to support founders with portfolio/business planning, fundraising and strategic partnerships.

Alicia obtained her Ph.D. in Biochemistry from Brown University.